<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885012</url>
  </required_header>
  <id_info>
    <org_study_id>00046009</org_study_id>
    <nct_id>NCT02885012</nct_id>
  </id_info>
  <brief_title>Crossover Study From Macitentan or Bosentan Over to Ambrisentan</brief_title>
  <acronym>Letairis</acronym>
  <official_title>A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan (Letairis®) After a Switch From Bosentan (Tracleer®) or Macintentan (Opsumit®) in Treatment of Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the safety and effects of switching
      treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24
      weeks in subjects with Connective Tissue Disease associated Pulmonary Arterial Hypertension
      (CTD-PAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a group of subjects who have been on bosentan for at least three
      months and a group that has been on macitentan for at least three months. Both groups will be
      switched to Letairis 5mg daily after the bosentan or macitentan therapy for three months and
      then increased to a dose of Letairis 10mg daily at week 4 if well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke Volume</measure>
    <time_frame>24 Weeks</time_frame>
    <description>ECHO Composite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome</measure>
    <time_frame>24 Weeks</time_frame>
    <description>EmPHasis-10 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>NT-proBNP Biomarker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Switch to Letairis from Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Letairis from Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <description>At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.</description>
    <arm_group_label>Switch to Letairis from Bosentan</arm_group_label>
    <arm_group_label>Switch to Letairis from Macitentan</arm_group_label>
    <other_name>Letairis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a Connective Tissue Disease (CTD)

          -  Age range: 18-80 years old

          -  Previous Right Heart Catheterization (RHC) demonstrating PAH

          -  Forced vital capacity (FVC) greater than 50%

          -  Carbon Monoxide Diffusing Capacity (DLCO) greater than 50%

          -  World Health Organization (WHO) functional class II or III

          -  Able to perform a 6 minute walk test (6MWT)

          -  Stable dose of antihypertensive medications

          -  Non-pregnant females

          -  Have to be currently on stable dose of bosentan for at least 3 months

          -  Adequate acoustic images to allow for transthoracic echocardiography to be performed

        Exclusion Criteria:

          -  Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)

          -  Severe systemic hypertension greater than 170/95

          -  Patients with a prior history of cardiovascular disease

          -  WHO functional class IV status

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study.

          -  FVC less than 50% of predicted

          -  DLCO less than 50% of predicted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terrill Huggins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Warden</last_name>
    <phone>843-792-4349</phone>
    <email>jonesash@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Bode</last_name>
      <phone>504-842-1936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Warden</last_name>
      <phone>843-792-4349</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>J. Terrill Huggins</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

